Published in final edited form as:

Curr Protoc Immunol. 2012 August ; CHAPTER: Unit-7.31. doi:10.1002/0471142735.im0731s98.

Isolation of Human Eosinophils

Praveen Akuthota¹, Revital Shamri¹, and Peter F. Weller¹

¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Abstract

Highly purified eosinophils can be isolated from peripheral blood by negative selection using an antibody-based magnetic negative selection protocol. The basic protocol describes a sequential fractionation of peripheral blood in which CD16+ granulocytes are enriched first from whole blood, followed by isolation of eosinophils. This technique is easy to use, fast, and highly reproducible. Support protocols describe a staining methods that can be used to evaluate the purity of eosinophils and differentiation from other leukocyte populations.

Keywords

eosinophils; cell separation; staining; labeling

INTRODUCTION

Highly purified eosinophils can be isolated from peripheral blood by negative selection using an antibody-based magnetic negative selection protocol. The Basic Protocol describes a sequential fractionation of peripheral blood in which granulocytes are enriched first from whole blood, followed by isolation of eosinophils. This technique is easy to use, fast, and highly reproducible. Support Protocol 1 describes a staining method to microscopically detect eosinophils using fast green and neutral red dyes. This allows one to evaluate the purity of eosinophils. Support Protocol 2 describes how to use a Wright-Giemsa-like stain (Hema 3) that allows for differentiation of granulocyte populations in cytospin slides of eosinophil preparations.

CAUTION: When working with human blood, cells, or infectious agents, biosafety practices should be followed (see Chapter 7 introduction).

BASIC PROTOCOL. ANTIBODY-BASED MAGNETIC NEGATIVE SELECTION OF EOSINOPHILS

This protocol describes leukocyte isolation from whole blood using dextran sedimentation, followed by granulocyte enrichment using Ficoll-Paque. Eosinophil isolation from granulocytes is performed by antibody-based negative selection using antibody cocktail against T cells, B cells, NK cells, monocytes, neutrophils, and erythrocytes.

Materials

Human blood donor

Acidified sodium citrate (see recipe), sterile

6% Dextran 70 in 0.9% NaCl (Pharmacosmos)

Ficoll-Paque Premium (GE Healthcare)

HBSS without Ca²⁺, Mg²⁺, or phenol red (*APPENDIX 2A*), 4°C

0.2% NaCl and 1.6% NaCl, 4°C

Turk Blood Diluting Fluid (Ricca Chemical Company)

Human eosinophil enrichment kit (StemCell Technologies; negative selection kit with negative selection antibody cocktail) including:

Monoclonal antibodies in cocktail include: anti-CD2 (to deplete residual T cells), anti-CD14 (to deplete residual monocytes), anti-CD16 (to deplete residual neutrophils), anti-CD19 (to deplete residual B-cells), anti-CD56 (to deplete residual NK cells), anti-glycophorin A (to deplete residual red blood cells), and anti-dextran

Magnetic colloid

Separation medium: 0.5% (w/v) OVA in HBSS without Ca^{2+} , Mg^{2+} , or phenol red (*APPENDIX 2A*), 4°C (alternatively, PBS with 2% FBS is available from StemCell Technologies as a separation medium and may be used)

Sterile 60-ml Luer-lock syringes

19-G butterfly needles

50-ml conical polypropylene centrifuge tubes

Benchtop refrigerated centrifuge for 50-ml conical tubes (Eppendorf 5810R or equivalent)

Sterile disposable transfer pipets

Magnetic separation apparatus capable of accommodating 0.5- or 0.6-in. magnetic columns (StemCell Technologies) kept in cold room

0.5- or 0.6-in. negative selection gravity-feed column (StemCell Technologies) with 3-way Luer stopcock assembly

21-G needles

Additional reagents and equipment for obtaining peripheral blood by venipuncture (*APPENDIX 3F*), counting cells with a hemacytometer (*APPENDIX 3A*), and eosinophil staining with fast green/neutral red (or Hema 3 eosin-based staining, see Support Protocols 1 and 2)

NOTE: All reagents and equipment coming into contact with live cells must be sterile, and proper sterile technique should be followed accordingly.

Isolate granulocytes

- 1 Draw 40 ml of blood from a human donor by venipuncture as in *APPENDIX 3F*, except use a 60-ml syringe equipped with a 19-G butterfly needle and prefilled with 10 ml of acidified sodium citrate. Retract the plunger with minimal traction until the syringe is filled to the 50-ml mark, then remove the syringe and (if desired) attach successive additional syringes (prefilled with the same solution) to the butterfly, repeating the drawing of blood until the desired amount of blood has been obtained. Remove the needle from the final syringe and place in a biosafety sharp container.

Activated platelets stick to eosinophils. The use of a large-bore needle and larger amounts of acidified sodium citrate prevents platelet activation. Aspirate blood with minimal traction to avoid platelet activation resulting from shear forces. Also see Critical Parameters.

From 320 ml of venous blood drawn from a nonatopic, nonallergic donor, $5\text{--}15 \times 10^6$ cells may be expected (numbers will vary from donor to donor).

- 2 Add 10 ml of 6% Dextran 70 in 0.9% NaCl to each syringe and gently invert (8 times) to mix the dextran with the blood. (Hetastarch, an alternative to Dextran, may also be used.) Let the syringes stand upright on their plungers for 45 to 60 min at room temperature inside a tissue culture hood.
- 3 Express the upper granulocyte-rich plasma layer from each upright syringe (~15 to 25 ml) by attaching a fresh 19-G butterfly needle (with the needle tip removed) to the syringe and pushing down on the plunger. Collect plasma in sterile 50-ml conical tubes.
- 4 Prepare an appropriate number of 50-ml conical polypropylene centrifuge tubes (usually one tube per 40 ml of blood drawn), each containing 23 ml room temperature Ficoll-Paque. Overlay with 20 to 25 ml of the expressed granulocyte-rich plasma. Using a benchtop refrigerated centrifuge for 50-ml conical tubes, centrifuge 20 min at $300 \times g$, room temperature, without using the centrifuge brake.

After centrifugation, mononuclear cells (lymphocytes and monocytes) and basophils are at the interface (white ring) between the plasma (the upper straw-colored layer) and the Ficoll-Paque (clear layer), whereas granulocytes (eosinophils and neutrophils) and erythrocytes are in the pellet. However, with blood from eosinophilic patients—e.g., patients with some hypereosinophilic syndromes—lower density eosinophils may also be found between the plasma/Ficoll-Paque interface (the mononuclear cell layer) and the pellet. In addition, some lower density eosinophils may also be present in the mononuclear layer itself.

- 5 Aspirate off the plasma and mononuclear layer as completely as possible from each tube, making sure to include any drops adhering to the wall of the tube. Then change the transfer pipets and aspirate the Ficoll-Paque layer, followed by an additional change of transfer pipets. In collecting the cells in the remaining pellet, bring the transfer pipet all the way down to the bottom of the conical tube and avoid splashing or contact with the tube wall to minimize contamination from any adherent mononuclear cells. Resuspend the pellet with 1 ml HBSS using a sterile disposable transfer pipet. If more than one conical tube has been loaded in the Ficoll-Paque step, pool the resuspended granulocytes from each tube in a 50-ml polypropylene centrifuge tube. Bring the volume up to 50 ml with 4°C HBSS. If more than four syringes of blood have been drawn, split the granulocyte yield into two 50-ml tubes

Cells should be kept on ice and wash solutions should be used at 4°C from this point in the protocol forward in order to minimize eosinophil activation.

(For the collection of lower density eosinophils: For each tube, aspirate and discard only the mononuclear cell layer and the plasma above it. Resuspend the pellet in the Ficoll-Paque solution and transfer into a new tube, then dilute the pellet and remaining Ficoll-Paque with at least an equal volume of 4°C HBSS to allow lower density eosinophils to be pelleted.)

- 6 Centrifuge the tube(s) for 5 min at $300 \times g$, 4°C , discard the supernatant(s), and dilute to 50 ml with 4°C HBSS.

The cells are washed twice to remove any adherent platelets and density-gradient medium.

- 7 *Optional:* Resuspend the erythrocyte-granulocyte pellet in the residual supernatant fluid with gentle agitation. Lyse the erythrocytes by adding 23 ml of 0.2% NaCl, as briefly as possible (<30 sec), then restore isotonicity by adding 23 ml of 1.6% NaCl. To minimize cell damage, avoid vortexing the cells vigorously. Centrifuge the tube(s) 5 min at $300 \times g$, 4°C , and wash the pellet twice with HBSS.

For functional eosinophil studies, we do not recommend erythrocyte lysis. The negative selection technique with anti-glycophorin A in the antibody cocktail is highly efficient at exclusion of erythrocytes (>97% to 99% purity). However, for some applications, the elimination of all possibility of erythrocyte contamination is paramount, so lysis may be employed under these circumstances.

- 8 *Count granulocytes:* Dilute 10 μl of cell suspension with 10 μl of Turk Blood Diluting Fluid (to lyse remaining red blood cells), and count granulocytes with a hemacytometer (*APPENDIX 3A*). Remember to account for dilution when calculating total number of granulocytes.
- 9 Centrifuge the cell suspension for 5 min at $300 \times g$, 4°C , in order to pellet granulocytes. Aspirate and discard the supernatant; loosen the pellet by gentle manual agitation and resuspend in 1 ml separation medium per 50×10^6 cells. Keep on ice.

Isolate eosinophils with negative-selection antibody cocktail

- 10 Add 100 μl antibody cocktail for human eosinophil negative selection per 50×10^6 cells.
- 11 Incubate the granulocyte suspension with antibody cocktail for 20 min at 4°C .
- 12 For each 50×10^6 cells, add 60 μl magnetic colloid to the cell-antibody suspension and incubate for 20 min at 4°C .

Agitate the tube periodically throughout the incubation to ensure proper mixture with antibodies.

- 13 In a cold room or 4°C refrigerated cabinet, attach a 21-G needle to the 3-way Luer stopcock assembly, place a negative selection column into the slot of magnetic separation apparatus, and wash the column with 20 ml of separation medium. Allow the fluid in the column to drop to the top level of the stainless steel mesh and close the three-way stopcock. Do not allow any portion of the stainless steel mesh to become dry.

A 21-G needle will allow a flow rate of 3.5 ml/min.

Also, see Critical Parameters. Avoid overloading the column by limiting the cell suspension to 3.0×10^8 magnetically bound cells per 0.5-in column and 1.5×10^9 cells per 0.6-in. column.

- 14 Transfer the cell-antibody-colloid suspension to the top of the column. Open the 3-way stopcock and allow the cell suspension to enter the steel mesh. Once the top of the cell suspension has entered the steel mesh, begin to collect the effluent in a sterile 50-ml conical tube. Wash the column using 3 to 5 column volumes (12 to 20 ml) of separation medium. Keep the column effluent at 4°C .

Non-eosinophil cells with bound immunomagnetic colloid will adhere to the magnetized column whereas eluted eosinophils will be in the wash effluent.

- 15 Determine the number of collected cells by counting in a hemacytometer (*APPENDIX 3A*). Determine the purity of the cells collected by staining a cytospin preparation of the cell suspension with fast green/neutral red staining or Hema 3 staining (see Support Protocols 1 and 2).

Alternatively, the purity of the eosinophil preparation can be ascertained by flow cytometry (see Chapter 5). Eosinophils stain positively with anti-Siglec-8 (Floyd et al., 2000) or anti-CCR3 antibody (Kitaura et al., 1996).

SUPPORT PROTOCOL 1. FAST GREEN AND NEUTRAL RED STAINING OF EOSINOPHILS

Fast green is a water-soluble, bluish-green, anionic triphenylmethane dye, which stains cytoplasmic granules of eosinophils green. Neutral red is a cationic azine dye, which stains nucleoproteins red. When used together, these dyes are useful in performing differential staining of eosinophils in cytospin preparations.

Materials

Purified eosinophil suspension (see Basic Protocol)

Methanol

0.2% (w/v) fast green (Sigma-Aldrich) in 70% ethanol (store up to 1 month at room temperature in polypropylene tube)

0.5% (w/v) neutral red (Sigma-Aldrich) in distilled water (store up to 1 month at room temperature in polypropylene tube)

Microscope slides

Cytocentrifuge (Cytospin, Shandon/Lipshaw)

1. Label the slides and insert them into the carriage assembly of the Cytospin cytocentrifuge according to the manufacturer's instructions.
2. Load a volume of purified eosinophil suspension containing 5×10^4 cells on each slide.
3. Spin the slides for 4 min at 350 rpm ($16 \times g$) in the Cytospin centrifuge.
4. Air dry the slides and fix by immersing for 1 min in methanol.
5. Immerse the slides for 10 min in 0.2% fast green solution, and then wash with running tap water. (Staining may be done longer, including overnight. Overstaining is not an issue.)
6. Immerse the slides for 5 min in 0.5% neutral red for 5 min (or longer), then wash with running tap water and air dry.

Slides are now ready for microscopic examination. Eosinophils are identified by their dark green-staining cytoplasmic granules and red-staining bilobed nuclei. Other leukocytes will exhibit only the red staining of their mononuclear or polylobular nuclei.

SUPPORT PROTOCOL 2. HEMA 3 STAINING OF EOSINOPHILS

Hema 3 (Fischer Scientific) is a Wright-Giemsa-like stain that allows for differentiation of granulocyte populations in cytospin slides of eosinophil preparations.

Materials

Purified eosinophil suspension (see Basic Protocol)

Deionized water

Hema 3 kit (Fisher Scientific, cat. no. 122-911) containing:

Fixative solution: 0.0002% (w/v) fast green in methanol

Solution 1: contains 0.125% (w/v) eosin Y, <0.55% (w/v) potassium phosphate monobasic, <0.4% (w/v) sodium phosphate dibasic, 0.01% sodium azide, in water

Solution 2: contains 0.0625% (w/v) azure A, 0.0625% (w/v) methylene blue, <0.55% (w/v) potassium phosphate monobasic, <0.4% (w/v) sodium phosphate dibasic, 0.01% sodium azide, in water

Microscope slides

Cytocentrifuge (Cytospin, Shandon/Lipshaw)

1. Label the slides and insert them into the carriage assembly of the Cytospin cytocentrifuge according to the manufacturer's instructions.
2. Load a volume of purified eosinophil suspension containing 5×10^4 cells on each slide.
3. Spin the slides for 4 min at 350 rpm ($16 \times g$) in the Cytospin centrifuge.
4. Air dry the slides and immerse for 50 sec in fixative solution.
5. Immerse the slides for 30 sec in solution 1.
6. Immerse the slides for 60 sec in solution 2, then wash slide with deionized water and air dry.

Slides are now ready for microscopic examination. Eosinophils are identified by their pink, granular cytoplasm and bilobed purple nuclei. The cytoplasm of contaminating neutrophils will not stain pink.

REAGENTS AND SOLUTIONS

Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see **APPENDIX 2A** for suppliers, see **APPENDIX 5**.

Sodium citrate, acidified (pH 5.2)

Acidified sodium citrate: Dissolve 37.3 g sodium citrate and 8 g citric acid in 450 ml distilled water. Adjust the pH to 5.2 with NaOH, and then adjust volume to 500 ml with water. Sterilize by filtration through 0.22- μ m filters. Store up to 2 weeks at 4°C.

COMMENTARY

Background Information

The application of negative selection techniques to the isolation of eosinophils has enabled researchers to consistently obtain eosinophils of high purity and number, even from nonhypereosinophilic donors (Hansel et al., 1990, 1991; Miltenyi et al., 1990). The system

described in this unit is the StemSep system from StemCell Technologies. Commercially available negative selection systems are available from R&D Systems and Miltenyi Biotec as well. A noncolumn-based magnetic negative selection system is also available from StemCell Technologies.

The StemSep system employs binding of antibody to epitopes present on neutrophils, T cells, B cells, NK cells, and monocytes for the purpose of negative selection of these cell populations. While density gradient centrifugation isolates granulocytes, negative selection is necessary to eliminate neutrophils and other contaminating nongranulocyte populations. The negative selection cocktail contains antibody complexes against the following antigens: CD2 (*T cells*), CD14 (*monocytes*), CD16 (*neutrophils*), CD19 (*B-cells*), CD56 (*NK cells*), and glycophorin A (*red blood cells*). These tetrameric antibody complexes also bind to the dextran contained in the magnetic colloid (Lansdorp and Thomas, 1990), allowing for magnetic separation of the desired eosinophil population from the undesired, magnetically bound populations by passing the cell suspension through a strong magnetic field (0.6 Tesla) in the presence of a stainless steel mesh column. The binding reaction is rapid and the quantity of antibody needed is relatively small (similar to that used for staining in flow cytometry). For detailed background on the principles of immunomagnetic negative selection of cells from peripheral blood, see *UNIT 7.4*.

Separation of eosinophils by differential density centrifugation with metrizoate (Day, 1970), metrizamide (Vadas et al., 1979), and Percoll (Gartner, 1980) were procedures previously employed. These are technically more difficult and tedious, and require eosinophilic donors. Moreover, the yield of eosinophils from the Percoll gradient is low (38% to 56%) and the purity is variable (86% to 99%; Gartner, 1980).

Differences in some biological responses have been observed when eosinophils are isolated by Percoll density centrifugation, anti-CD16 beads, and α Met-Leu-Phe activation (Yazdanbakhsh et al., 1987; Laviolette et al. 1993; Blom et al., 1995). This may be related, in part, to the fact that homogeneous-density eosinophils are isolated by density centrifugation, whereas a heterogeneous population of normodense and hypodense eosinophils are isolated by negative selection. Eosinophils may also be activated during the negative selection isolation procedure, given that human eosinophils can express CD16 (Hartnell et al., 1992; Sedgwick et al., 1996). This may be important in certain disease states. With these considerations in mind, the immunomagnetic purification procedure is nonetheless an easy and highly reproducible method of isolating eosinophils.

Critical Parameters

StemCell negative selection columns are available in different sizes, with varying optimal cell ranges. The 0.5-in. column is suitable for 5×10^7 – 3×10^8 cells, and the 0.6-in. column is suitable for 1×10^8 – 1.5×10^9 cells. A flow rate of <1 column volume/min for washing is optimal. A 21-G needle will have a flow rate of 3.5 ml/min; therefore, use of this size needle will ensure efficient washing.

Solutions used throughout the density gradient separation step, including citrate, dextran, and Ficoll-Paque should be brought to room temperature prior to use. After isolation of granulocytes, all solutions must be kept at 4°C. It is imperative to use only polypropylene tubes. The donor should be advised not to engage in vigorous exercise prior to donating blood, as this causes the number of circulating neutrophils to increase and necessitates the use of larger amounts of negative selection antibody cocktail. Activated platelets adhere readily to eosinophils and are thus a potential source of contamination. However, the measures adopted during blood drawing, the choice of acidified citrate as anticoagulant, and the extra washing during cell processing should help to eliminate this problem. To avoid

mononuclear cell contamination, it is best to overlay rather than to underlay the leukocyte-rich plasma onto the Ficoll-Paque, taking care to form a sharp plasma–Ficoll-Paque interface. After centrifugation, the mononuclear layer should consist of a narrow band at the interface. Care should also be exercised in aspirating this band to ensure its complete removal. To remove mononuclear cells adherent on the wall of the conical tube, the latter can be swabbed with a sterile cotton-tip swab.

Ammonium chloride lysis of erythrocytes is not recommended because this reagent interferes with eosinophil antigen processing and cytokine responses and alters cellular morphology (Ide et al., 1994; Wang et al., 2007). We previously suggested red blood cell lysis with hypotonic saline, and another recently published protocol (Munoz and Leff, 2006) recommends red blood cell lysis with sterile water. However, we have adopted a protocol without red blood cell lysis given the potential for eosinophil granule abnormalities with red blood cell lysis (Malm-Erfjelt et al., 2004). High purity is observed (>97% to 99%) in most donors in the absence of red blood cell lysis with the combination of red blood cell sedimentation and the presence of anti-glycophorin A antibody in the negative selection cocktail. It should be noted that occasionally greater red blood cell contamination might be seen. We leave red blood cell lysis with hypotonic saline as an optional step for situations in which complete red blood cell elimination is required. It should be noted that elimination of red blood cells from the protocol makes sedimentation of red blood cells an absolute requirement. We prefer the use of dextran, as opposed to the manufacturer's recommendation of hetastarch. This choice is due to observations that hetastarch may lead to more abnormalities in granule morphology than dextran (personal observations; Jackson et al., 1989.)

It is important not to overload the magnetic column; use a column size appropriate to the number of cells being processed or use multiple columns, if necessary. Perform the differential count immediately after the cells come off the column.

Troubleshooting

See Table 7.31.1 for common problems in eosinophil isolation, along with possible causes and solutions.

Anticipated Results

With the StemCell negative selection system, eosinophils of >97% to 99% purity can routinely be obtained. From 320 ml of venous blood from a nonatopic, nonallergic donor, $5\text{--}15 \times 10^6$ cells may be expected, though results are variable.

Time Considerations

The whole protocol takes 4 to 5 hr to perform.

Acknowledgments

Drs. Praveen Akuthota and Revital Shamri contributed equally to work done in this unit. This work was supported by National Institutes of Health grants R01 AI051645 and R01/R37 AI020241 (to PFW) and F32 AI081513 (to PA).

Literature Cited

Blom M, Tool A, Mul F, Knol E, Roos D, Verhoeven A. Eosinophils isolated with two different methods show different characteristics of activation. *J Immunol Methods*. 1995; 178:183–193. [PubMed: 7836780]

- Day R. Eosinophil cell separation from human peripheral blood. *Immunology*. 1970; 18:955. [PubMed: 5428871]
- Floyd H, Ni J, Cornish AL, Zeng Z, Liu D, Carter KC, Steel J, Crocker PR. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. *J Biol Chem*. 2000; 275:861–866. [PubMed: 10625619]
- Gartner I. Separation of human eosinophils in density gradients of polyvinylpyrrolidone-coated silica gel (Percoll). *Immunology*. 1980; 40:133–136. [PubMed: 6252099]
- Hansel T, Pound J, Thompson R. Isolation of eosinophils from human blood. *J Immunol Methods*. 1990; 127:153–164. [PubMed: 2179410]
- Hansel TT, de Vries IJM, Iff T, Rihs S, Wandzilak M, Betz S, Blaser K, Walker C. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. *J Immunol Methods*. 1991; 145:105–110. [PubMed: 1662676]
- Hartnell A, Kay AB, Wardlaw AJ. IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. *J Immunol*. 1992; 148:1471–1478. [PubMed: 1311348]
- Ide M, Weiler D, Kita H, Gleich GJ. Ammonium chloride exposure inhibits cytokine-mediated eosinophil survival. *J Immunol Methods*. 1994; 168:187–196. [PubMed: 8308293]
- Jackson MH, Millar AM, Dawes J, Bell D. Neutrophil activation during cell separation procedures. *Nucl Med Commun*. 1989; 10:901–904. [PubMed: 2622592]
- Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany HL, Murphy PM, Yoshie O. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. *J Biol Chem*. 1996; 271:7725–7730. [PubMed: 8631813]
- Lansdorp PM, Thomas TE. Purification and analysis of bispecific tetrameric antibody complexes. *Mol Immunol*. 1990; 27:659–666. [PubMed: 1697645]
- Lavolette M, Bossé M, Rocheleau H, Lavigne S, Ferland C. Comparison of two modified techniques for purifying blood eosinophils. *J Immunol Methods*. 1993; 165:253–261. [PubMed: 8228275]
- Malm-Erfjelt M, Stevens TR, Persson CG, Erfjelt JS. Discontinuous Percoll gradient centrifugation combined with immunomagnetic separation obviates the need for erythrocyte lysis and yields isolated eosinophils with minimal granule abnormalities. *J Immunol Methods*. 2004; 288:99–109. [PubMed: 15183089]
- Miltenyi S, Müller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. *Cytometry*. 1990; 11:231–238. [PubMed: 1690625]
- Munoz NM, Leff AR. Highly purified selective isolation of eosinophils from human peripheral blood by negative immunomagnetic selection. *Nat Protoc*. 2006; 1:2613–2620. [PubMed: 17406516]
- Sedgwick JB, Shikama Y, Nagata M, Brener K, Busse WW. Effect of isolation protocol on eosinophil function: Percoll gradients versus immunomagnetic beads. *J Immunol Methods*. 1996; 198:15–24. [PubMed: 8914593]
- Vadas MA, David JR, Butterworth A, Pisani NT, Siongkok TA. A new method for the purification of human eosinophils and neutrophils and a comparison of these cells to damage schistosomula of *Schistosoma mansoni*. *J Immunol*. 1979; 122:2950–2958.
- Wang HB, Ghiran I, Matthaei K, Weller PF. Airway eosinophils: Allergic inflammation recruited professional antigen-presenting cells. *J Immunol*. 2007; 179:7585–7592. [PubMed: 18025204]
- Yazdanbakhsh M, Eckmann C, Koenderman L, Verhoeven A, Roos D. Eosinophils do respond to fMLP. *Blood*. 1987; 70:379–383. [PubMed: 3607277]

Table 7.31.1**Troubleshooting Guide for Isolation by Negative Selection of Human Eosinophils**

Problem	Possible cause	Solution
Mononuclear cell contamination	Poor layering on density solution	Check technique of overlaying onto Ficoll-Paque
	Density separation disrupted by braking	Make sure the centrifuge brake is off during density centrifugation
	Mononuclear layer incompletely aspirated	Check technique of aspirating off the mononuclear layer after Ficoll-Paque centrifugation
Neutrophil (or mononuclear cell) contamination	Not enough antibody added	Use proper amount of antibody
	Antibody cocktail and/or magnetic colloid are expired	Use fresh antibody cocktail and/or magnetic colloid
	The column was overloaded	Load fewer cells or use two columns
	Excessive flow rate through column applied (may result in a brown-tinged pellet due to the presence of magnetic colloid)	Reload the eluted cells onto the column and apply the recommended flow rate
Red blood cell contamination	Sedimentation and antibody cocktail are inadequate to eliminate red blood cells	Use red blood cell lysis protocol
Platelet contamination	Blood drawn with small-bore needle	Use 19-G needle
	Blood drawn with vigorous traction applied to syringe plunger	Draw blood more gently
	Not enough anticoagulant used	Increase anticoagulant
	Ice-cold HBSS was not calcium- and magnesium-free	Prepare HBSS properly
Poor cell viability	Improper solution pH or contaminated solutions or column.	Prepare new solutions; carefully wash the re-used column according to manufacture instructions.